BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects
Recruitment status was Not yet recruiting
The goal of this study is to evaluate the proportion of subjects both antiretroviral experienced and virologically suppressed on lopinavir/ritonavir (LPV/r)400/100mg twice daily who maintain viral suppression after switching to lopinavir/ritonavir (LPV/r)800/200mg once daily.
The hypothesis for this study is that the majority of subjects will remain virologically suppressed with once daily dosing versus twice daily dosing and therefore quality of life will be improved with the once daily dosing of lopinavir/ritonavir (LPV/r)800/200mg.
|Study Design:||Observational Model: Defined Population
Time Perspective: Longitudinal
|Official Title:||BLADE: "A Comparison of Once Daily LPV/r to LPV/r BID in HIV-Infected Virologically Controlled Antiretroviral Experienced Subjects"|
|Contact: Keri Neuling||214-828-4702 ext firstname.lastname@example.org|
|Contact: Denise Ramos||214-828-4702 ext email@example.com|
|United States, Texas|
|Nicholaos C. Bellos, MD||Not yet recruiting|
|Dallas, Texas, United States, 75204|
|Contact: Keri Neuling 214-828-4702 ext 122 firstname.lastname@example.org|
|Contact: Denise Ramos 214-828-4702 ext 102 email@example.com|
|Principal Investigator: Nicholaos C. Bellos, MD|
|Principal Investigator:||Nicholaos C. Bellos, MD||Nicholaos C. Bellos, MD|